Key facts
- This page summarizes Frank E. Thomas's Form 4 filing for Orchard Therapeutics plc.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Mar 2023, 08:30.
Frank E. Thomas - 10 Mar 2023 Form 4 Insider Report for Orchard Therapeutics plc
- Reporting relationship
- Title: President & Chief Operating Officer
- Issuer ticker
- N/A
- Reported as of
- 10 Mar 2023
- Net transaction value
- +$9,182
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2023, 08:30:50 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 11 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frank Thomas
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Frank E. Thomas filed Form 4 for Orchard Therapeutics plc on 14 Mar 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: +$9,182.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORTX
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $9,182
- Shares
- +20,000
- Change %
- +28%
- Price
- $0.4591
- Shares after
- 92,081
- Date
- 10 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -5.6%
- Price
- $0.000000
- Shares after
- 335,000
- Date
- 10 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 20,000
- Exercise price
- $0.4591
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.
Footnote F2
The shares subject to this option vest and become exercisable in twenty-four (24) equal monthly installments, with the first installment vested on March 1, 2022.
SEC remarks
Title: President & Chief Operating Officer